Patient-independent variables affecting the assessment of aspirin responsiveness by serum thromboxane measurement
- 1 September 2016
- journal article
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 116 (11) , 891-896
Abstract
The serum TXB2 (sTXB2) assay reflects the pharmacodynamics of platelet inhibition by low-dose aspirin. However, different studies reported variable sTXB2 values. sTXB2 assay requires whole blood incubation at 37 °C as a condition for optimal thrombin generation, arachidonic acid release and its metabolism by platelet cyclooxygenase-1 to form TXA2. Access to 37 °C incubation may be variably delayed, and different methods to quantitate sTXB2 may contribute to variable results between different Centers. We investigated whether delaying 37 °C incubation and/or analytical issues affect sTXB2 concentrations, biasing the assessment of aspirin responsiveness. Sixty-eight samples from 54 volunteers, on- and off-aspirin, were incubated at 37 °C immediately after sampling (reference sample) or after 5, 10, 15, 20, 30 or 60 minutes at room temperature (RT); 8 samples remained at RT 60 minutes, without subsequent incubation; 314 sera were measured by enzyme immunoassay (EIA) and liquid chromatography-tandem mass-spectrometry (LC/MS-MS) methods. sTXB2 concentrations decreased exponentially as a function of the delay before 37 °C incubation, ranging from 94 ± 11 % at 5 minutes to 23 ± 22 % of the reference sample after 60 minutes at RT. There was high agreement between EIA and LC/MS-MS. Moreover, we simulated the influence of a 15– or 30-minute delayed incubation on 300 sTXB2 measurements from previously-studied, aspirin-treated patients. Delayed incubation reduced the percentage of aspirin ‘non-responders’ by 22 % to 52 %, depending on the response threshold. In conclusion, a variable delay in the 37 °C incubation of blood samples may affect the assessment of platelet cyclooxygenase-1 inhibition by aspirin and confound the characterization of the determinants of aspirin responsiveness.Keywords
Funding Information
- Innovative Medicines Initiative (D3.2 2013–70201169)
This publication has 23 references indexed in Scilit:
- The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low‐dose aspirin in patients with and without diabetesJournal of Thrombosis and Haemostasis, 2012
- Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug targetBlood, 2012
- Protease-Activated Receptor Signaling in Platelets Activates Cytosolic Phospholipase A2αDifferently for Cyclooxygenase-1 and 12-Lipoxygenase CatalysisArteriosclerosis, Thrombosis, and Vascular Biology, 2011
- Association of Cyclooxygenase-1-Dependent and -Independent Platelet Function Assays With Adverse Clinical Outcomes in Aspirin-Treated Patients Presenting for Cardiac CatheterizationCirculation, 2009
- Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed plateletsProceedings of the National Academy of Sciences, 2002
- Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patientsBMJ, 2002
- The Coxibs, Selective Inhibitors of Cyclooxygenase-2New England Journal of Medicine, 2001
- Clinical pharmacology of platelet cyclooxygenase inhibition.Circulation, 1985
- Selective Cumulative Inhibition of Platelet Thromboxane Production by Low-dose Aspirin in Healthy SubjectsJournal of Clinical Investigation, 1982
- Low dose aspirin and inhibition of thromboxane B2 production in healthy subjectsThrombosis Research, 1980